[
    [
        {
            "time": "2020-01-30",
            "original_text": "Edited Transcript of LLY earnings conference call or presentation 30-Jan-20 2:00pm GMT",
            "features": {
                "keywords": [
                    "LLY",
                    "earnings",
                    "conference",
                    "call",
                    "presentation"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Edited Transcript of LLY earnings conference call or presentation 30-Jan-20 2:00pm GMT",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2020-01-30",
            "original_text": "Eli Lilly prices migraine therapy at $640 for pack of eight pills",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "migraine",
                    "therapy",
                    "pricing"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly prices migraine therapy at $640 for pack of eight pills",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-01-30",
            "original_text": "Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription",
            "features": {
                "keywords": [
                    "REYVOW",
                    "lasmiditan",
                    "migraine",
                    "treatment"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-01-30",
            "original_text": "Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative",
            "features": {
                "keywords": [
                    "LLY",
                    "PFE",
                    "Q4",
                    "results",
                    "JNJ",
                    "vaccine",
                    "coronavirus"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2020-01-30",
            "original_text": "Bayer Seeks FDA Approval for New Formulation of Nifurtimox",
            "features": {
                "keywords": [
                    "Bayer",
                    "FDA",
                    "approval",
                    "Nifurtimox"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Bayer Seeks FDA Approval for New Formulation of Nifurtimox",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-01-30",
            "original_text": "The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",
            "features": {
                "keywords": [
                    "Amgen",
                    "generic",
                    "competition",
                    "Nanoviricides",
                    "Wuhan",
                    "virus",
                    "Arcutis",
                    "IPO"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",
                "Correlation": 2,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2020-01-30",
            "original_text": "CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes",
            "features": {
                "keywords": [
                    "CHMP",
                    "Lilly",
                    "insulin",
                    "glycemic",
                    "control",
                    "diabetes"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]